Drugs / APG-5918
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05773586 | Mar 2023 → Dec 2027 expected | anemia | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05415098 | Sep 2022 → Sep 2024 | B-cell non-Hodgkin lymphoma, castration-resistant prostate carcinoma, epithelioid sarcoma, gastric cancer +3 | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-04-19 | Ascentage Pharma Group Inc. | Results Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting ascentage.com ↗
In vivo, APG-5918 combined with irinotecan demonstrated synergistic antitumor activity in the NCI-H446 SCLC cell-derived xenograft (CDX) model without significant body-weight loss, indicating favorable tolerability. |
| 2025-06-15 | Ascentage Pharma Group Inc. | Results EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL ascentage.com ↗
These data showed the potent antitumor activity of APG-5918 in T-cell lymphoma and support further clinical development of the agent. |
| 2025-04-28 | Ascentage Pharma Group Inc. | Results Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax ascentage.com ↗
today announced that it has presented results from five preclinical studies during poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois, USA. |
| 2024-04-07 | Ascentage Pharma Group Inc. | Results AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting ascentage.com ↗
We are pleased to present the preclinical research data of four assets in our pipeline at the AACR 2024. |
| 2024-03-06 | Ascentage Pharma Group Inc. | Results AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting ascentage.com ↗
Results from this preclinical study show that in preclinical models of PCa, targeting both EED and MDM2 can synergistically enhance antitumor activities by modulating pathways related to DNA methylation, cell cycle, and apoptosis. |
| 2022-11-14 | Ascentage Pharma Group Inc. | Regulatory Ascentage Pharma Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies ascentage.com ↗
Ascentage Pharma (6855.HK) today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to enter a Phase I study in patients with advanced solid tumors or hematologic malignancies. |
| 2022-04-14 | Ascentage Pharma Group Inc. | Results AACR 2022 | Ascentage Presents Six Preclinical Studies ascentage.com ↗
APG-5918 was thoroughly characterized in the preclinical stage, with potent biochemical binding activity to EED protein, in vitro anti-proliferatively activity, and in vivo antitumor activities. |
| 2022-03-09 | Ascentage Pharma Group Inc. | Results Ascentage to Present Six Preclinical Studies at AACR 2022 ascentage.com ↗
These six abstracts from Ascentage Pharma include: |
| 2021-10-18 | Ascentage Pharma Group Inc. | Results JMC Publishes Study Showing Potential of EED Inhibitor EEDi-5273 ascentage.com ↗
The study found that the oral administration of EEDi-5273 is capable of achieving complete and persistent tumor regression in the KARPAS422 xenograft model in mice. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APG-5918 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05773586 ↗ |
| Route | Oral | “APG-5918 will be orally administered once every day on 28-day cycles.” NCT05415098 ↗ |